Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hepatitis

Free Subscription Articles published in Hepatology Retrieve available abstracts of 265 articles: HTML format

Single Articles

April 2024
1. DUNN W, Li Y, Singal AK, Simonetto DA, et al
   An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.
   Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000883.
   PubMed     Abstract available
   
   
   
2. CHOI WM, Lim YS
   "Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients".
   Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000884.
   PubMed    
   
   
   
3. HE T, Zhang D
   Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
   Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000882.
   PubMed    
   
   
   March 2024
4. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
   Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
   Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
   PubMed     Abstract available
   
   
   
5. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
   Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
   Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
   PubMed     Abstract available
   
   
   
6. PERRILLO RP, Janssen HLA
   Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000810.
   PubMed    
   
   
   
7. KONDILI LA, Craxi A
   Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
   PubMed    
   
   
   
8. GRATACOS-GINES J, Ruz-Zafra P, Celada-Sendino M, Marti-Carretero A, et al
   Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000825.
   PubMed     Abstract available
   
   
   February 2024
9. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
   Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
   Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
   PubMed     Abstract available
   
   
   
10. YAMAZAKI T, Kouno T, Hsu CL, Hartmann P, et al
    Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000777.
    PubMed     Abstract available
    
    
    
11. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    PubMed    
    
    
    
12. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    PubMed    
    
    
    
13. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    PubMed    
    
    
    
14. DIMOU A, Zachou K, Kostara C, Azariadis K, et al
    NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis.
    Hepatology. 2024 Feb 5. doi: 10.1097/HEP.0000000000000767.
    PubMed     Abstract available
    
    
    January 2024
15. CHOI WM, Yip TC, Kim WR, Yee LJ, et al
    Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752.
    PubMed     Abstract available
    
    
    
16. 
    Erratum: Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
    Hepatology. 2024 Jan 19. doi: 10.1097/HEP.0000000000000759.
    PubMed    
    
    
    
17. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    PubMed     Abstract available
    
    
    
18. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    PubMed     Abstract available
    
    
    December 2023
19. KINAST V, Todt D
    The relation of host genetics and symptomatic hepatitis E.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000749.
    PubMed    
    
    
    
20. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    PubMed    
    
    
    
21. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    PubMed    
    
    
    
22. YIP TC, Brunetto MR
    Hepatitis B surface antigen seroclearance is uncommon but durable in the long run.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000741.
    PubMed    
    
    
    
23. SAADAT A, Gouttenoire J, Ripellino P, Semela D, et al
    Inborn errors of type I interferon immunity in patients with symptomatic acute hepatitis E.
    Hepatology. 2023 Dec 8. doi: 10.1097/HEP.0000000000000701.
    PubMed     Abstract available
    
    
    November 2023
24. SHEN J, Zhang K, Liu M, Wang T, et al
    Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000682.
    PubMed    
    
    
    
25. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    PubMed     Abstract available
    
    
    
26. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
    Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
    PubMed     Abstract available
    
    
    
27. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    PubMed    
    
    
    
28. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    PubMed    
    
    
    
29. DE CARVALHO RIBEIRO M, Babuta M, Szabo G
    Reply: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000686.
    PubMed    
    
    
    
30. BRUDEN D, McMahon BJ, Snowball M, Towshend-Bulson L, et al
    Rate and durability of clearance of hepatitis B surface antigen in Alaska Native persons with long-term hepatitis B virus infection: 1982-2019.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000658.
    PubMed     Abstract available
    
    
    
31. LEE CH, Mak LY, Tang EH, Lui DT, et al
    SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
    Hepatology. 2023;78:1569-1580.
    PubMed     Abstract available
    
    
    October 2023
32. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    PubMed    
    
    
    
33. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    PubMed    
    
    
    
34. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    PubMed     Abstract available
    
    
    
35. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    PubMed    
    
    
    
36. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    PubMed    
    
    
    
37. ELSHEIKH R, Makram AM, Huy NT
    Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000625.
    PubMed    
    
    
    
38. JAGADISAN B, Dhawan A
    Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000622.
    PubMed    
    
    
    September 2023
39. CHOLANKERIL G, Vierling JM
    The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough!
    Hepatology. 2023 Sep 18. doi: 10.1097/HEP.0000000000000597.
    PubMed    
    
    
    
40. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    PubMed     Abstract available
    
    
    
41. GILL US, Peppa D
    Pegylated interferon-alpha for chronic hepatitis B...not ready to be shelved yet! new insights on its role using single-cell transcriptomics.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000560.
    PubMed     Abstract available
    
    
    August 2023
42. JENG WJ, Chien RN, Chen YC, Lin CL, et al
    Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
    PubMed     Abstract available
    
    
    
43. CHANG X, Lv C, Wang B, Wang J, et al
    The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
    Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000563.
    PubMed     Abstract available
    
    
    
44. JIANPING D, Xi C, Guangwen C, Fankun M, et al
    Dual elastography to discriminate adjacent stages of fibrosis and inflammation in chronic hepatitis B: A prospective multicenter study.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000566.
    PubMed     Abstract available
    
    
    
45. LI Y, Wen C, Gu S, Wang W, et al
    Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy.
    Hepatology. 2023;78:592-606.
    PubMed     Abstract available
    
    
    July 2023
46. MA X, Ding WX
    Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
    PubMed    
    
    
    
47. HU X, Shen J, Wang T, Liu M, et al
    Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
    PubMed    
    
    
    
48. CABRE N, Hartmann P, Llorente C, Kouno T, et al
    IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice.
    Hepatology. 2023;78:295-306.
    PubMed     Abstract available
    
    
    
49. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    PubMed     Abstract available
    
    
    June 2023
50. JENG WJ, Liaw YF
    Letter to the Editor: Proper monitoring instead of expanding treatment for improving prognosis of indeterminate phase hepatitis B patients.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000526.
    PubMed    
    
    
    
51. HUANG DQ, Nguyen MH
    Reply: Proper monitoring instead of expanding treatment for improving prognosis of indeterminate phase hepatitis B patients.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000525.
    PubMed    
    
    
    
52. JIANG P, Jia H, Qian X, Tang T, et al
    Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-alpha in patients with chronic hepatitis B.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000524.
    PubMed     Abstract available
    
    
    
53. GHANY MG, Buti M, Lampertico P, Lee HM, et al
    Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D- Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference.
    Hepatology. 2023 Jun 21. doi: 10.1097/HEP.0000000000000431.
    PubMed     Abstract available
    
    
    
54. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    PubMed     Abstract available
    
    
    
55. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    PubMed    
    
    
    
56. DA BL
    Clinical trials in hepatitis D virus: Measuring success.
    Hepatology. 2023;77:2147-2157.
    PubMed     Abstract available
    
    
    May 2023
57. LOK J, Dusheiko G
    Editorial: Re-assessing antiviral treatment criteria for chronic hepatitis B.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000496.
    PubMed    
    
    
    
58. TONON M, Balcar L, Semmler G, Calvino V, et al
    Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
    Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
    PubMed     Abstract available
    
    
    
59. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
    Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
    PubMed     Abstract available
    
    
    
60. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    PubMed    
    
    
    
61. GENSHAFT AS, Subudhi S, Keo A, Sanchez Vasquez JD, et al
    Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients.
    Hepatology. 2023 May 10. doi: 10.1097/HEP.0000000000000438.
    PubMed     Abstract available
    
    
    
62. NG CH, Chan KE, Muthiah M, Tan C, et al
    Examining the interim proposal for name change to steatotic liver disease in the US population.
    Hepatology. 2023;77:1712-1721.
    PubMed     Abstract available
    
    
    
63. HOWELL J, Seaman C, Wallace J, Xiao Y, et al
    Pathway to global elimination of hepatitis B: HBV cure is just the first step.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000430.
    PubMed     Abstract available
    
    
    April 2023
64. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
    Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
    PubMed     Abstract available
    
    
    
65. SONNEVELD MJ, Brouwer WP, Janssen HLA
    Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?
    Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000424.
    PubMed    
    
    
    
66. GHANY MG, King WC, Hinerman AS, Lok AS, et al
    Use of HBV RNA and hepatitis B core-related antigen to predict change in serological status and disease activity in CHB.
    Hepatology. 2023 Apr 20. doi: 10.1097/HEP.0000000000000413.
    PubMed     Abstract available
    
    
    
67. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    PubMed    
    
    
    
68. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available
    
    
    
69. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available
    
    
    
70. CHAO X, Wang S, Ma X, Zhang C, et al
    Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000373.
    PubMed     Abstract available
    
    
    
71. STEINMANN S, Lohse AW
    Treatment of autoimmune hepatitis: Budesonide does not solve our problems.
    Hepatology. 2023;77:1071-1073.
    PubMed    
    
    
    
72. TAN DJH, Setiawan VW, Ng CH, Lim WH, et al
    Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH.
    Hepatology. 2023;77:1150-1163.
    PubMed     Abstract available
    
    
    March 2023
73. MAK LY, Yuen MF, Seto WK
    Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
    PubMed    
    
    
    
74. HUANG SC, Kao JH
    Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
    PubMed    
    
    
    
75. DE CARVALHO RIBEIRO M, Iracheta-Vellve A, Babuta M, Calenda CD, et al
    Alcohol-induced extracellular asc specks perpetuate liver inflammation and damage in alcoholic hepatitis even after alcohol cessation.
    Hepatology. 2023 Mar 3. doi: 10.1097/HEP.0000000000000298.
    PubMed     Abstract available
    
    
    
76. WU X, Fan X, McMullen MR, Miyata T, et al
    Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis.
    Hepatology. 2023;77:902-919.
    PubMed     Abstract available
    
    
    
77. LEGGIO L, Mellinger JL
    Alcohol use disorder in community management of chronic liver diseases.
    Hepatology. 2023;77:1006-1021.
    PubMed     Abstract available
    
    
    February 2023
78. SZABO G, Mitchell M, Dasarathy S, McClain C, et al
    Reply: Survival in placebo-treated patients with severe alcoholic hepatitis".
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000337.
    PubMed    
    
    
    
79. VAN MELKEBEKE L, Pollentier L, Van der Merwe S, Nevens F, et al
    Letter to the editor: survival in placebo-treated patients with severe alcoholic hepatitis.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000336.
    PubMed    
    
    
    
80. 
    Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
    PubMed    
    
    
    
81. ETZION O, Hamid S, Lurie Y, Gane EJ, et al
    Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000309.
    PubMed     Abstract available
    
    
    
82. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
    Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
    PubMed     Abstract available
    
    
    
83. ABDUL MAJEED N, Zehnder B, Koh C, Heller T, et al
    Hepatitis delta: epidemiology to recent advances in therapeutic agents.
    Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000331.
    PubMed    
    
    
    
84. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    PubMed    
    
    
    
85. LISKER-MELMAN M, Wahed AS, Ghany MG, Chung RT, et al
    HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
    Hepatology. 2023;77:594-605.
    PubMed     Abstract available
    
    
    January 2023
86. HSU CC, Dodge JL, Weinberg E, Im G, et al
    Multi-Centered study of patient outcomes after declined for early liver transplantation in severe Alcohol-associated hepatitis.
    Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000267.
    PubMed     Abstract available
    
    
    
87. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available
    
    
    
88. CUNNINGHAM M, Gupta R, Butler M
    Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
    PubMed     Abstract available
    
    
    
89. DIAZ-GONZALEZ A, Hernandez-Guerra M, Perez-Medrano I, Sapena V, et al
    Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000018.
    PubMed     Abstract available
    
    
    
90. WU J, Kim A, Wu X, Ray S, et al
    5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000024.
    PubMed     Abstract available
    
    
    October 2022
91. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    PubMed     Abstract available
    
    
    September 2022
92. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
    PubMed    
    
    
    
93. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    PubMed     Abstract available
    
    
    
94. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    PubMed    
    
    
    
95. YING D, He Q, Tian W, Chen Y, et al
    Urine Is a Viral Antigen Reservoir in Hepatitis E Virus Infection.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32745.
    PubMed     Abstract available
    
    
    
96. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    PubMed     Abstract available
    
    
    
97. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    PubMed     Abstract available
    
    
    
98. PAL S, Dey D, Chakraborty BC, Nandi M, et al
    Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
    Hepatology. 2022;76:759-774.
    PubMed     Abstract available
    
    
    August 2022
99. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
    Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
    PubMed    
    
    
    
100. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
     Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
     Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
     PubMed     Abstract available
     
     
     
101. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
     Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
     Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
     PubMed     Abstract available
     
     
     
102. WU Y, Hao X, Wei H, Sun R, et al
     TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
     Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
     PubMed     Abstract available
     
     
     July 2022
103. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
     Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
     Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.
     PubMed    
     
     
     
104. SHEHRYAR M, Asif MZ, Umair M
     Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
     Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.
     PubMed    
     
     
     
105. NASSAL M
     How many steps to a feasible mouse model of hepatitis B virus infection?
     Hepatology. 2022 Jul 24. doi: 10.1002/hep.32684.
     PubMed    
     
     
     
106. ELSHEIKH R, Tien HT, Makram AM, Van NT, et al
     Acute Hepatitis of Unknown Origin in Children: Behind the Statistics.
     Hepatology. 2022 Jul 21. doi: 10.1002/hep.32682.
     PubMed     Abstract available
     
     
     
107. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
     Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
     Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
     PubMed    
     
     
     
108. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
     Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
     Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
     PubMed    
     
     
     
109. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
     Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
     Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
     PubMed     Abstract available
     
     
     
110. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
     Getting to HBV cure: The promising paths forward.
     Hepatology. 2022;76:233-250.
     PubMed     Abstract available
     
     
     
111. WU CR, Kim HJ, Sun CP, Chung CY, et al
     Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants.
     Hepatology. 2022;76:207-219.
     PubMed     Abstract available
     
     
     
112. SINGH SP, Mishra AK, Jindal A
     IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
     Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.
     PubMed    
     
     
     
113. GUPTA S, Nath P, Anand AC
     Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
     Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.
     PubMed    
     
     
     June 2022
114. BARNES E, Cooke GS, Lauer G, Chung RT, et al
     Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
     Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
     PubMed     Abstract available
     
     
     
115. ZHAO K, Guo F, Wang J, Zhong Y, et al
     Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
     Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
     PubMed     Abstract available
     
     
     
116. XU C, Fan J, Liu D, Tuerdi A, et al
     Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
     Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
     PubMed     Abstract available
     
     
     
117. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
     Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
     Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
     PubMed     Abstract available
     
     
     
118. AHMAD A
     Letter to the Editor: Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
     Hepatology. 2022 Jun 11. doi: 10.1002/hep.32607.
     PubMed     Abstract available
     
     
     
119. AHMAD A, Chaudhry HUR
     Letter to the Editor: Outcomes of pregnancy in autoimmune hepatitis: A population-based study.
     Hepatology. 2022 Jun 10. doi: 10.1002/hep.32600.
     PubMed    
     
     
     
120. WANG CY, Deng Y, Li P, Zheng S, et al
     Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
     Hepatology. 2022;75:1373-1385.
     PubMed     Abstract available
     
     
     May 2022
121. HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
     Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
     Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
     PubMed     Abstract available
     
     
     
122. CHUNG Y, Heneghan MA
     Reply to: Medical therapy of autoimmune hepatitis in pregnancy.
     Hepatology. 2022 May 19. doi: 10.1002/hep.32579.
     PubMed    
     
     
     
123. EFE C, Purnak T
     Medical therapy of Autoimmune hepatitis in pregnancy.
     Hepatology. 2022 May 18. doi: 10.1002/hep.32576.
     PubMed    
     
     
     
124. EFE C, Kulkarni AV, Beretta-Piccoli BT, Magro B, et al
     Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
     Hepatology. 2022 May 14. doi: 10.1002/hep.32572.
     PubMed     Abstract available
     
     
     
125. NEUMANN-HAEFELIN C, Thimme R
     Another important step towards a prophylactic vaccine against hepatitis C.
     Hepatology. 2022 May 3. doi: 10.1002/hep.32557.
     PubMed    
     
     
     
126. MULCAHY VL, Mells GF
     Commentary on Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
     Hepatology. 2022 May 2. doi: 10.1002/hep.32547.
     PubMed    
     
     
     
127. PAPATHEODORIDI M, Tampaki M, Lok AS, Papatheodoridis GV, et al
     Risk of HBV reactivation during therapies for HCC: A systematic review.
     Hepatology. 2022;75:1257-1274.
     PubMed     Abstract available
     
     
     April 2022
128. KUMAR A, Rajani D, Kumar S
     Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
     Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
     PubMed    
     
     
     
129. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
     Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
     Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
     PubMed     Abstract available
     
     
     
130. LUCEY MR, Thursz M
     We need a new approach to clinical trials in alcohol-associated hepatitis. Is there a lesson in RECOVERY?
     Hepatology. 2022 Apr 13. doi: 10.1002/hep.32523.
     PubMed    
     
     
     
131. COFFIN CS
     The remarkable success of the vaccine for a killer virus: Hepatitis B.
     Hepatology. 2022 Apr 11. doi: 10.1002/hep.32346.
     PubMed    
     
     
     
132. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
     Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
     PubMed     Abstract available
     
     
     
133. WAT C, Gane E, Yuen MF, Pavlovic V, et al
     Reply.
     Hepatology. 2022;75:1050-1051.
     PubMed    
     
     
     March 2022
134. SUNDARAM V, Jalan R
     Letter to the editor: the role of acute-on-chronic liver failure in predicting recovery in severe alcoholic hepatitis.
     Hepatology. 2022 Mar 31. doi: 10.1002/hep.32495.
     PubMed    
     
     
     
135. DENG R, Liu S, Shen S, Guo H, et al
     Circulating hepatitis B virus RNA: From biology to clinical applications.
     Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
     PubMed     Abstract available
     
     
     
136. SZABO G, Mitchell M, McClain CJ, Dasarathy S, et al
     IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
     Hepatology. 2022 Mar 27. doi: 10.1002/hep.32478.
     PubMed     Abstract available
     
     
     
137. BRUCE MG, Bruden D, Hurlburt D, Morris J, et al
     Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose.
     Hepatology. 2022 Mar 23. doi: 10.1002/hep.32474.
     PubMed     Abstract available
     
     
     
138. LOUKACHOV V, van Dort K, Erken R, Reesink HW, et al
     Reponse to: Letter to the Editor concerning Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
     Hepatology. 2022 Mar 23. doi: 10.1002/hep.32472.
     PubMed    
     
     
     
139. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
     A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
     Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
     PubMed     Abstract available
     
     
     
140. HE Q, Zhang F, Shu J, Li S, et al
     Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
     Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
     PubMed     Abstract available
     
     
     
141. HOWELL J, Hellard M
     Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
     Hepatology. 2022 Mar 9. doi: 10.1002/hep.32450.
     PubMed    
     
     
     
142. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
     Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
     Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.
     PubMed    
     
     
     
143. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
     Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
     PubMed     Abstract available
     
     
     February 2022
144. PATWA AK, Rungta S, Kumar V
     Nanoparticle therapeutic vaccine for hepatitis B: an unfulfilled dream.
     Hepatology. 2022 Feb 28. doi: 10.1002/hep.32421.
     PubMed    
     
     
     
145. D'AMBROSIO R, Lampertico P
     Is it time to refine HCC surveillance strategies in HCV cured patients?
     Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
     PubMed    
     
     
     
146. ZHANG J, Zhao T, Wei L, Wu Y, et al
     Reply: epsilonPA-44 may expand the arsenal for chronic hepatitis B combination treatment towards functional cure.
     Hepatology. 2022 Feb 24. doi: 10.1002/hep.32423.
     PubMed    
     
     
     
147. PERRILLO RP, Lin HS, Schwarz KB, Rosenthal P, et al
     Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.
     Hepatology. 2022 Feb 21. doi: 10.1002/hep.32400.
     PubMed     Abstract available
     
     
     
148. LI Y, Sun Y, Liu Y, Wang B, et al
     Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
     Hepatology. 2022 Feb 19. doi: 10.1002/hep.32417.
     PubMed     Abstract available
     
     
     
149. CHUNG YY, Heneghan MA
     Autoimmune hepatitis in pregnancy: pearls and pitfalls.
     Hepatology. 2022 Feb 19. doi: 10.1002/hep.32410.
     PubMed     Abstract available
     
     
     
150. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
     Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
     Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
     PubMed     Abstract available
     
     
     
151. TU T, Zhang H
     Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32388.
     PubMed    
     
     
     
152. YANG Y, Choi J, Chen Y, Invernizzi P, et al
     E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
     Hepatology. 2022;75:266-279.
     PubMed     Abstract available
     
     
     
153. WANG X, Wei Z, Cheng B, Li J, et al
     Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis.
     Hepatology. 2022;75:438-454.
     PubMed     Abstract available
     
     
     January 2022
154. HUANG V, Lewin C, Novy P
     Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the US.
     Hepatology. 2022 Jan 31. doi: 10.1002/hep.32376.
     PubMed    
     
     
     
155. JANG H, Lee YB, Moon H, Chung JW, et al
     Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
     Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
     PubMed     Abstract available
     
     
     
156. PAN CQ, Jacobson IM, Martin P, Kwo P, et al
     Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
     Hepatology. 2022 Jan 28. doi: 10.1002/hep.32366.
     PubMed    
     
     
     
157. ERKEN R, Loukachov V, van Dort K, van den Hurk A, et al
     Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
     Hepatology. 2022 Jan 24. doi: 10.1002/hep.32352.
     PubMed     Abstract available
     
     
     
158. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
     Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
     Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
     PubMed     Abstract available
     
     
     
159. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
     Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
     Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
     PubMed     Abstract available
     
     
     
160. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
     Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
     Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
     PubMed     Abstract available
     
     
     
161. PAN JJ, Razumilava N
     Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: is less more?
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32330.
     PubMed    
     
     
     
162. SANDMANN L, Cornberg M
     Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
     PubMed    
     
     
     
163. JINDAL A
     Oral antivirals in treatment naive chronic hepatitis C infection.
     Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.
     PubMed    
     
     
     
164. GINES P, Castera L, Lammert F, Graupera I, et al
     Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
     Hepatology. 2022;75:219-228.
     PubMed     Abstract available
     
     
     December 2021
165. COHEN C, Moraras K, Jackson M, Kamischke M, et al
     Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
     Hepatology. 2021 Dec 24. doi: 10.1002/hep.32304.
     PubMed    
     
     
     
166. CHEN VL, Ramrakhiani NS, Nguyen MH
     Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.
     Hepatology. 2021 Dec 24. doi: 10.1002/hep.32303.
     PubMed    
     
     
     
167. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
     A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
     Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
     PubMed     Abstract available
     
     
     
168. SUZUKI Y, Kakisaka K, Takikawa Y
     Letter to the Editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population based-epidemiological study.
     Hepatology. 2021 Dec 13. doi: 10.1002/hep.32280.
     PubMed    
     
     
     
169. MUSTO J, Lucey MR, Rice J
     Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32275.
     PubMed    
     
     
     
170. JINDAL A
     Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32276.
     PubMed    
     
     
     
171. WEI L, Ploss A
     Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles.
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32273.
     PubMed    
     
     
     
172. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
     Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
     Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
     PubMed    
     
     
     
173. CAO Z, Gui H, Sheng Z, Xin H, et al
     Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
     Hepatology. 2021 Dec 4. doi: 10.1002/hep.32269.
     PubMed     Abstract available
     
     
     
174. YURDAYDIN C, Keskin O, Yurdcu E, Caliskan A, et al
     A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32259.
     PubMed     Abstract available
     
     
     
175. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
     Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
     Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
     PubMed     Abstract available
     
     
     
176. HE WQ, Guo GN, Li C
     The impact of hepatitis B vaccination in United States, 1999-2018.
     Hepatology. 2021 Dec 2. doi: 10.1002/hep.32265.
     PubMed     Abstract available
     
     
     
177. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
     A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
     Hepatology. 2021;74:2974-2987.
     PubMed     Abstract available
     
     
     
178. ISNARD P, Larue M, Pitsch A, Duong Van Huyen JP, et al
     A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease.
     Hepatology. 2021;74:3549-3551.
     PubMed    
     
     
     November 2021
179. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
     'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.
     Hepatology. 2021 Nov 19. doi: 10.1002/hep.32248.
     PubMed     Abstract available
     
     
     
180. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
     Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".
     Hepatology. 2021 Nov 19. doi: 10.1002/hep.32249.
     PubMed     Abstract available
     
     
     
181. WANG Y, Li Y, Zai W, Hu K, et al
     Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage.
     Hepatology. 2021 Nov 15. doi: 10.1002/hep.32245.
     PubMed     Abstract available
     
     
     
182. POLITI J, Guerras JM, Donat M, Belza MJ, et al
     Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
     Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
     PubMed     Abstract available
     
     
     
183. TABERNERO D, Cortese MF, Rando-Segura A, Buti M, et al
     Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.
     Hepatology. 2021 Nov 10. doi: 10.1002/hep.32227.
     PubMed     Abstract available
     
     
     
184. TERRAULT NA, Wahed AS, Feld JJ, Cooper SL, et al
     Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32231.
     PubMed     Abstract available
     
     
     
185. KUIPERY A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, et al
     Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32230.
     PubMed     Abstract available
     
     
     
186. ROY A, Dhiman RK
     Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
     Hepatology. 2021;74:2909.
     PubMed    
     
     
     
187. GHANY MG, King WC, Lisker-Melman M, Lok ASF, et al
     Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
     Hepatology. 2021;74:2395-2409.
     PubMed     Abstract available
     
     
     
188. SHEN Y, Cingolani F, Malik SA, Wen J, et al
     Sex-Specific Regulation of Interferon-gamma Cytotoxicity in Mouse Liver by Autophagy.
     Hepatology. 2021;74:2745-2758.
     PubMed     Abstract available
     
     
     
189. LEE BT, Tana MM, Kahn JA, Dara L, et al
     We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
     Hepatology. 2021;74:2876-2887.
     PubMed     Abstract available
     
     
     
190. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
     Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
     Hepatology. 2021;74:2714-2724.
     PubMed     Abstract available
     
     
     October 2021
191. BEKKI Y, Fenig Y
     Outcomes of Severe Alcohol-Related Hepatitis with or without Early Liver Transplantation.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32219.
     PubMed     Abstract available
     
     
     
192. LI M, Wong D, Vogel AS, Sack JS, et al
     Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
     Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
     PubMed     Abstract available
     
     
     
193. KHANAM A, Kottilil S, Tang LSY
     PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.
     Hepatology. 2021 Oct 24. doi: 10.1002/hep.32210.
     PubMed     Abstract available
     
     
     
194. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
     Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
     PubMed     Abstract available
     
     
     
195. HU K, Camila Perez-Matos M, Argemi J, Vilar E, et al
     Lipoprotein Z, A novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32203.
     PubMed     Abstract available
     
     
     
196. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
     BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
     Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
     PubMed     Abstract available
     
     
     
197. KUSHNER T, Chappell CA
     Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
     Hepatology. 2021;74:2311-2312.
     PubMed    
     
     
     
198. MA Y, Su H, Yuksel M, Longhi MS, et al
     Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
     Hepatology. 2021;74:2032-2046.
     PubMed     Abstract available
     
     
     September 2021
199. YASSEEN AS, Kwong JC, Feld JJ, Kustra R, et al
     The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
     Hepatology. 2021 Sep 19. doi: 10.1002/hep.32162.
     PubMed     Abstract available
     
     
     
200. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
     Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
     Hepatology. 2021 Sep 15. doi: 10.1002/hep.32156.
     PubMed     Abstract available
     
     
     
201. HUANG R, Liu J, Wang J, Li J, et al
     Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
     Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
     PubMed     Abstract available
     
     
     
202. RAMRAKHIANI NS, Chen VL, Le M, Yeo YH, et al
     Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.
     Hepatology. 2021 Sep 8. doi: 10.1002/hep.32142.
     PubMed     Abstract available
     
     
     
203. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
     Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
     Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
     PubMed     Abstract available
     
     
     
204. TAUBERT R, Engel B, Diestelhorst J, Hupa-Breier KL, et al
     Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.
     Hepatology. 2021 Sep 2. doi: 10.1002/hep.32134.
     PubMed     Abstract available
     
     
     
205. DING WB, Wang MC, Yu J, Huang G, et al
     HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
     Hepatology. 2021;74:1480-1495.
     PubMed     Abstract available
     
     
     
206. STERLING RK, King WC, Khalili M, Chung RT, et al
     A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
     Hepatology. 2021;74:1174-1189.
     PubMed     Abstract available
     
     
     
207. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
     Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
     Hepatology. 2021;74:1148-1163.
     PubMed     Abstract available
     
     
     August 2021
208. WANG CW, Grab J, Tana MM, Irani RA, et al
     Outcomes of Pregnancy in Autoimmune Hepatitis: A Population-Based Study.
     Hepatology. 2021 Aug 28. doi: 10.1002/hep.32132.
     PubMed     Abstract available
     
     
     
209. WEI L, Zhao T, Zhang J, Mao Q, et al
     Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32109.
     PubMed     Abstract available
     
     
     
210. LI Y, Yu P, Kessler AL, Shu J, et al
     Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32114.
     PubMed     Abstract available
     
     
     
211. YIP TC, Wong VW, Wong GL
     Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32116.
     PubMed     Abstract available
     
     
     
212. JINDAL A
     Outcomes in chronic hepatitis B infection and COVID-19 - Not always benign !
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32108.
     PubMed     Abstract available
     
     
     
213. OECHSLIN N, Da Silva N, Szkolnicka D, Cantrelle FX, et al
     Hepatitis E Virus RNA-Dependent RNA Polymerase is Involved in RNA Replication and Infectious Particle Production.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32100.
     PubMed     Abstract available
     
     
     
214. LV XH, Yang JL, Deng K
     Letter to the Editor: unanswered questions about hepatitis B virus infection in patients with COVID-19.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32098.
     PubMed     Abstract available
     
     
     
215. MUSTO J, Stanfield D, Ley D, Lucey MR, et al
     Recovery and Outcomes of Patients Denied Early Liver Transplantation (LT) for Severe Alcohol-Related Hepatitis (AH).
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32110.
     PubMed     Abstract available
     
     
     
216. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
     Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
     PubMed     Abstract available
     
     
     
217. TOYODA H, Leong J, Landis C, Atsukawa M, et al
     Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
     Hepatology. 2021;74:656-666.
     PubMed     Abstract available
     
     
     
218. LIANG YJ, Teng W, Chen CL, Sun CP, et al
     Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
     Hepatology. 2021;74:641-655.
     PubMed     Abstract available
     
     
     July 2021
219. LOK AS, Negro F, Asselah T, Farci P, et al
     Endpoints and new options for treatment of chronic hepatitis D.
     Hepatology. 2021 Jul 31. doi: 10.1002/hep.32082.
     PubMed     Abstract available
     
     
     
220. CHOLANKERIL G, Goli K, Rana A, Hernaez R, et al
     Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States.
     Hepatology. 2021 Jul 26. doi: 10.1002/hep.32067.
     PubMed     Abstract available
     
     
     
221. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
     Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
     Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
     PubMed     Abstract available
     
     
     
222. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
     A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
     Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
     PubMed     Abstract available
     
     
     
223. KIM OK, Nam DE, Hahn YS
     The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
     Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
     PubMed     Abstract available
     
     
     
224. CHO Y, Szabo G
     Two Faces of Neutrophils in Liver Disease Development and Progression.
     Hepatology. 2021;74:503-512.
     PubMed     Abstract available
     
     
     June 2021
225. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
     Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
     Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
     PubMed     Abstract available
     
     
     
226. BEUDEKER BJB, Janssen HLA, Boonstra A
     Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
     PubMed     Abstract available
     
     
     
227. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
     Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
     PubMed     Abstract available
     
     
     
228. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
     Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
     PubMed     Abstract available
     
     
     
229. ROBERTS H, Ly KN, Yin S, Hughes E, et al
     Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
     Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
     PubMed     Abstract available
     
     
     
230. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
     Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
     Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
     PubMed     Abstract available
     
     
     
231. CHOI J, Yoo S, Lim YS
     Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
     Hepatology. 2021;73:2155-2166.
     PubMed     Abstract available
     
     
     May 2021
232. GANE E, Yuen MF, Kim DJ, Chan HL, et al
     Clinical Study of Single Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B.
     Hepatology. 2021 May 26. doi: 10.1002/hep.31920.
     PubMed     Abstract available
     
     
     
233. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
     Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
     PubMed     Abstract available
     
     
     
234. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
     Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
     PubMed     Abstract available
     
     
     
235. RIEDL T, Faure-Dupuy S, Rolland M, Schuehle S, et al
     HIF1alpha-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
     Hepatology. 2021 May 15. doi: 10.1002/hep.31902.
     PubMed     Abstract available
     
     
     
236. YIP TC, Wong VW, Lui GC, Chow VC, et al
     Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19.
     Hepatology. 2021 May 7. doi: 10.1002/hep.31890.
     PubMed     Abstract available
     
     
     
237. LIAO H, Wang J, Liu Y, Chen J, et al
     Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
     Hepatology. 2021;73:2075-2076.
     PubMed    
     
     
     
238. BRUNT EM, Kleiner DE, Carpenter DH, Rinella M, et al
     NAFLD: Reporting Histologic Findings in Clinical Practice.
     Hepatology. 2021;73:2028-2038.
     PubMed     Abstract available
     
     
     April 2021
239. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
     Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
     Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
     PubMed     Abstract available
     
     
     
240. LIU Y, Wang S, Hu L
     Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B.
     Hepatology. 2021 Apr 8. doi: 10.1002/hep.31842.
     PubMed     Abstract available
     
     
     
241. LEE YB, Lee J
     Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B - The Authors' reply.
     Hepatology. 2021 Apr 2. doi: 10.1002/hep.31844.
     PubMed     Abstract available
     
     
     
242. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
     Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
     Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
     PubMed     Abstract available
     
     
     
243. ABUTALEB A, Khatun M, Clement J, Baidya A, et al
     A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.
     Hepatology. 2021;73:1261-1274.
     PubMed     Abstract available
     
     
     February 2021
244. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
     Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
     Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
     PubMed     Abstract available
     
     
     
245. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
     Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
     Hepatology. 2021;73:861-864.
     PubMed    
     
     
     
246. KIM GW, Imam H, Khan M, Mir SA, et al
     HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.
     Hepatology. 2021;73:533-547.
     PubMed     Abstract available
     
     
     
247. CHEN J, Li Y, Lai F, Wang Y, et al
     Functional Comparison of Interferon-alpha Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-alpha and Interferon-gamma Signaling.
     Hepatology. 2021;73:486-502.
     PubMed     Abstract available
     
     
     
248. ZHAO X, Fan H, Chen X, Zhao X, et al
     Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.
     Hepatology. 2021;73:503-519.
     PubMed     Abstract available
     
     
     November 2020
249. HAFEZI M, Lin M, Chia A, Chua A, et al
     Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients.
     Hepatology. 2020 Nov 29. doi: 10.1002/hep.31662.
     PubMed     Abstract available
     
     
     
250. BERTOLETTI A
     ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection.
     Hepatology. 2020;72:1514-1517.
     PubMed    
     
     
     September 2020
251. ZHAO Q, Guo JT
     Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
     Hepatology. 2020;72:1142-1144.
     PubMed    
     
     
     August 2020
252. KAPILA N, Rahman AU, Zervos XB
     Reply.
     Hepatology. 2020;72:788.
     PubMed    
     
     
     July 2020
253. THAN NN, Cataluna JG, Majumdar A
     Acute confusion post liver transplantation: HE or not HE, that is the question.
     Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
     PubMed     Abstract available
     
     
     
254. CRESCI GAM
     Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?
     Hepatology. 2020;72:4-6.
     PubMed    
     
     
     April 2020
255. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
     Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
     Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
     PubMed     Abstract available
     
     
     
256. MCGLYNN KA, Petrick JL, El-Serag HB
     Epidemiology of Hepatocellular Carcinoma.
     Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
     PubMed     Abstract available
     
     
     
257. YANG Y, Zhao X, Wang Z, Shu W, et al
     Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
     Hepatology. 2020;71:1154-1169.
     PubMed     Abstract available
     
     
     March 2020
258. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
     HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
     Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
     PubMed     Abstract available
     
     
     
259. ZENG J, Wu D, Hu H, Young JAT, et al
     Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
     Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
     PubMed     Abstract available
     
     
     December 2019
260. STUART L, Lambourne B, Turner P, Jones DE, et al
     HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
     Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
     PubMed     Abstract available
     
     
     October 2019
261. LIU F, Goh GB, Tiniakos D, Wee A, et al
     qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
     Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
     PubMed     Abstract available
     
     
     September 2019
262. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
     Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
     Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
     PubMed     Abstract available
     
     
     
263. DONG B, Zhou Y, Wang W, Scott J, et al
     Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
     Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
     PubMed     Abstract available
     
     
     August 2019
264. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
     Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
     Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
     PubMed     Abstract available
     
     
     
265. ZHOU Y, Dong B, Kim KH, Choi S, et al
     Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
     Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.